Full Year 2024 Results Key Financial Results Revenue: US$4.44b (flat on FY ...

Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health’s Fourth Quarter 2024 Earnings Conference ...

Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement with South Dakota-based ...

Highlights,Elanco Animal Health reported a miss in earnings, with EPS falling short of expectations.,Analysts adjusted their ...

Elanco Animal Health inks agreement with Medgene to commercialize highly pathogenic avian influenza vaccine in dairy cattle: Greenfield, Indiana Wednesday, February 26, 2025, 15:0 ...

Stifel analyst Jonathan Block lowered the firm’s price target on Elanco (ELAN) to $15 from $16 and keeps a Buy rating on the shares. While the ...

Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $20 and keeps an Overweight rating on the shares. The firm sees a “solid ...

In a big win for House Speaker Mike Johnson, House Republicans got their budget plan through the chamber on a 217-215 vote.

The Prince Edward Island Bioscience Cluster continues to make its mark as a top driver of the province’s growing economy.

The Norway aquaculture vaccines market is projected to reach USD 125.6 million by 2025, expanding at a CAGR of 6.7% from 2025 to 2035. As a global leader in salmon farming, Norway plays a crucial role ...

Q4 2024 Earnings Call Transcript February 25, 2025 Tarsus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

This new RXE is the second to receive acceptance by the FDA for a longevity drug developed by Loyal. The first, LOY-001, received RXE acceptance in November 2023. LOY-001 is a prescription injection ...